Live Breaking News & Updates on United Biomedical Inc

Stay updated with breaking news from United biomedical inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insider Buying: Vaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Acquires 10,000 Shares of Stock

Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder United Biomedical Inc acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The stock was acquired at an average price of $2.95 per share, with a total value of $29,500.00. Following the acquisition, the insider now owns 51,626,366 shares in […] ....

United States , Geode Capital Management , Securities Exchange Commission , Virtu Financial , Zacks Investment Research , Investment Advisers , United Biomedical Inc , Vaxxinity Company Profile Get Rating , America Corp , Managers Group , Vaxxinity Inc , Get Rating , Exchange Commission , Biomedical Inc , Investment Research , Company Profile , Lewy Body , Nasdaq Vaxx , Insider Trading , Nsider Trades ,

-$0.38 Earnings Per Share Expected for Vaxxinity, Inc. (NASDAQ:VAXX) This Quarter

Brokerages expect Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) to report earnings of ($0.38) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vaxxinity’s earnings, with estimates ranging from ($0.40) to ($0.35). The firm is expected to issue its next earnings results on Monday, January 1st. On average, […] ....

United States , Geode Capital Management , Securities Exchange Commission , Goldman Sachs Group Inc , Zacks Investment Research , Investment Advisers , United Biomedical Inc , Vaxxinity Company Profile Get Rating , Managers Group , Vaxxinity Inc , Get Rating , Investment Research , Exchange Commission , Capital Management , Sachs Group , Adage Capital Partners , Company Profile , Lewy Body , Nasdaq Vaxx ,

Vaxxinity (NASDAQ:VAXX) Lifted to Buy at Zacks Investment Research

Vaxxinity (NASDAQ:VAXX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The brokerage currently has a $4.75 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of 9.95% from the […] ....

United States , Geode Capital Management , Securities Exchange Commission , Virtu Financial , Zacks Investment Research , Investment Advisers , United Biomedical Inc , Vaxxinity Company Profile Get Rating , Managers Group , Vaxxinity Inc , Millennium Management , Get Rating , Investment Research , Exchange Commission , Capital Management , Company Profile , Lewy Body , Nasdaq Vaxx ,

Vaxxinity (NASDAQ:VAXX) Lowered to "Hold" at Zacks Investment Research

Vaxxinity (NASDAQ:VAXX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Vaxxinity Inc. is a biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Vaxxinity Inc. is based in DALLAS, Texas. “ […] ....

United States , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Investment Advisers , United Biomedical Inc , Vaxxinity Company Profile Get Rating , Managers Group , Vaxxinity Inc , Get Rating , Capital Management , Sachs Group , Adage Capital Partners , Company Profile , Lewy Body , Nasdaq Vaxx ,